Compare HTT & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
High Templar Tech Limited American depositary shares each representing one Class A ordinary share
Current Price
| Metric | HTT | LBRX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 648.9M | 563.2M |
| IPO Year | N/A | 2025 |
| Metric | HTT | LBRX |
|---|---|---|
| Price | $3.41 | $20.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $49.00 |
| AVG Volume (30 Days) | 372.1K | ★ 531.1K |
| Earning Date | 03-19-2026 | 02-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2364.38 | N/A |
| EPS | ★ 0.67 | N/A |
| Revenue | ★ $12,647,260.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.36 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.04 | $13.36 |
| 52 Week High | $5.08 | $23.15 |
| Indicator | HTT | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.